#### Edgar Filing: Wells William McDowall - Form 4

Wells Willia	am McDowall								
Form 4									
January 31,	2012							0145	
FORM	<b>14</b>		SECU	DITIES A	ND EV	CHANCI	COMMERION		PPROVAL
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB Number:	3235-0287		
if no lon subject t Section Form 4 e Form 5 obligatio may con	rsuant to S (a) of the l	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940					Expires: Estimated burden hor response n	urs per	
<i>See</i> Instr 1(b).	ruction	50(II)	or the h	ivestillent	Compa	Ily Act of I	1940		
(Print or Type	Responses)								
1. Name and Address of Reporting Person <u>*</u> Wells William McDowall			2. Issuer Name <b>and</b> Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	. ,		3. Date of	of Earliest Tr Day/Year)	ransaction		Director Officer (give below)		% Owner her (specify
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
SAN DIEG	GO, CA 92121						Person		sporting
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securities A	Acquired, Disposed of	f, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transaction Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D)	SecuritiesFBeneficially()Owned()Following()Reported()Transaction(s)()	5. Ownership Form: Direct D) or Indirect I) Instr. 4)	Indirect
				Code V	Amount	(D) Price	(Instr. 3 and 4)		
Reminder: Re	port on a separate lin	e for each cl	ass of sec	urities benef	ficially ow	ned directly	or indirectly.		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: Wells William McDowall - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 I S (
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 1.6	01/27/2012		А	15,000	<u>(1)</u>	01/26/2022	Common Stock	15,000	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Wells William McDowall						
C/O ACADIA PHARMACEUTICALS INC.						
3911 SORRENTO VALLEY BLVD.						
SAN DIEGO, CA 92121						

## **Signatures**

/s/ Glenn F. Baity, Attorney-in-Fact

01/31/2012

\*\*Signature of Reporting Person

### Date **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- 50% of the shares subject to the Stock Option vest and become exercisable on each of the first and second anniversary of the date of (1) grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Ľ S C